Potency Assays for Thalassemia and Sickle Cell Disease Gene Therapy Drug Products

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Potency Assays for Thalassemia and Sickle Cell Disease Gene Therapy Drug Products</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Potency assays provide an invaluable means of testing and quantifying the efficacy of stem cell treatments."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Potency assays provide an invaluable means of testing and quantifying the efficacy of stem cell treatments."> <meta property="og:title" content="Potency Assays for Thalassemia and Sickle Cell Disease Gene Therapy Drug Products"> <meta name="twitter:description" content="Potency assays provide an invaluable means of testing and quantifying the efficacy of stem cell treatments."> <meta name="twitter:title" content="Potency Assays for Thalassemia and Sickle Cell Disease Gene Therapy Drug Products"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/potency-assays-for-ceb2-thalassemia-and-sickle-cell-disease-gene-therapy-drug-products"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/Potency%20Assays%20for%20Thalassemia%20and%20Sickle%20Cell%20Disease%20Gene%20Therapy%20Drug%20Products.png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="800"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/Potency%20Assays%20for%20Thalassemia%20and%20Sickle%20Cell%20Disease%20Gene%20Therapy%20Drug%20Products.png"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/potency-assays-for-ceb2-thalassemia-and-sickle-cell-disease-gene-therapy-drug-products"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Stem Cell Therapy | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Potency Assays for Thalassemia and Sickle Cell Disease Gene Therapy Drug Products </h1> <div class="byline"> 15 June 2022 </div> <div class="abstract"> In this Commentary article, we explore how reductions in testing complexity can improve access to hematopoietic stem cell therapies for patients with blood disorders. The provision of safe, effective therapies will help to ameliorate the worst impacts of these disorders for patients and afford them a better quality of life. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/Potency%20Assays%20for%20Thalassemia%20and%20Sickle%20Cell%20Disease%20Gene%20Therapy%20Drug%20Products.png" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>Presented by: <strong>Riccardo Biavasco</strong>, Senior Scientist at bluebird bio</p> <p></p> <p></p> <p>Edited by: <strong>Ben Norris</strong></p> <p></p> <p></p> <p>Diseases such as sickle cell anaemia – caused by a mutation that induces haemoglobin precipitation and subsequent sickling of red blood cells – can be treated through stem cell gene therapy. However, reproducing and quantifying the treatment process in vitro can be tricky, time-consuming, and expensive. Potency assays provide a means of testing and quantifying the efficacy of stem cell treatments. Riccardo Biavasco, Senior Scientist at bluebird bio, explains that assays that investigate the editing efficiencies are an effective and practical approach for testing and development of stem cell gene therapies.</p> <p></p> <p></p> <h2 id="h-potency-assay-development-for-cell-therapy"><strong>Potency Assay Development for Cell Therapy</strong></h2> <p></p> <p></p> <p>When it comes to the development of new treatments for cellular diseases like sickle cell disease, patient safety and treatment efficacy is paramount. “It's really important that we provide safe and effective therapies,” said Biavasco at Oxford Global's Cell Therapy Analytics Symposium in March 2022. Treatment efficacy is assessed through the use of potency assays, which are run to monitor the development of cell therapies and the suitability of drug products. “In our case these therapies are based on hematopoietic stem and progenitor cells (HSPCs), which are harvested thanks to mobilisation and apheresis,” he continued. HSPCs are modified to generate corrected red blood cells upon infusion, which ultimately provide the clinical benefits to ?-thalassemia and sickle cell disease patients.</p> <p></p> <p></p> <p>“Once enriched with the CD34 marker, the cells are transduced with lentiviral vectors that integrate the therapeutic transgene,” Biavasco explained. Modified HSPCs are subsequently cryopreserved, then tested for safety and efficacy, after which they can be infused into their source patients. bluebird bio runs a suite of potency assays to demonstrate that the integrated transgene is able to stably express the therapeutic protein and correct the disease phenotype. One of the key determinants is the vector copy number (VCN), which ensures that an appropriate amount of the lentiviral vector (LVV) is integrated in the drug product.</p> <p></p>  <p></p>   <h2 id="h-in-vitro-cell-therapy-analysis"><strong>In Vitro Cell Therapy Analysis</strong></h2>   <p>Biavasco then gave an overview of the physiologic process that bluebird bio's assays are modelling. “It all starts with the stem cells, the same ones that we want to correct in our patients,” he said. “These cells go through different steps of maturation, and they become more and more committed to the erythroid lineage until they start to really express the haemoglobin.” On reaching a haemoglobin threshold, the nucleus starts to condense, and once fully condensed is ejected from the cells.</p>   <ul><li><a href="https://oxfordglobal.com/cell/resources/upstream-bioprocessing/" target="_blank" rel="noreferrer noopener">Discussion Group Report: New Developments in Upstream Bioprocessing</a></li><li><a href="https://oxfordglobal.com/cell/resources/digital-twins-upstream-processing-applications-and-hybrid-models/" target="_blank" rel="noreferrer noopener">Digital Twins: Innovative Modelling Techniques for Secure Research</a></li><li><a href="https://oxfordglobal.com/cell/resources/future-directions-for-accelerated-upstream-bioprocessing/" target="_blank" rel="noreferrer noopener">What's Next for Upstream Processing?</a></li></ul>   <p></p>   <p>“It's one of the last steps in the maturation of red blood cells” said Biavasco. “So, this is what happens<em> in vivo</em>. We need to reproduce this <em>in vitro</em>, which is quite a challenge.” Fortunately, bluebird bio is up to the task and has developed a cell culture system that enables erythroid differentiation <em>in vitro</em>. In ?-thalassemia, cell growth and maturation are constrained by the absence of ?-globin. “Erythroid cells mature until they reach the point they really need haemoglobin, and there they get stuck,” Biavasco continued. The solution involves the administration of autologous CD34 hematopoietic stem cells to provide a continuous and durable source of corrected red blood cells.</p>   <figure class="wp-block-image size-full"><img src="https://oxfordglobal.com/wp-content/uploads/2022/07/Method-of-Action-Specific-Potency-866-Ã—-700px.jpg" alt="Potency assays; developing hematopoietic stem cells that mature into healthy red blood cells with the presence of HbAT87Q." class="wp-image-29282"><figcaption><strong><em>Figure. 1</em></strong><em> – Developing hematopoietic stem cells that mature into healthy red blood cells with the presence of HbA<sup>T87Q</sup>.</em></figcaption></figure>   <p></p>   <p>These HSPCs are transduced with an LVV-encoding human ?-globin with an amino acid substitution (T87Q). This substitution confers anti-sickling properties to the haemoglobin derived from gene therapy – HbA<sup>T87Q</sup> – which can subsequently be quantified in the erythroid progeny of transduced HSPCs. Biavasco added that two distinct potency assays, tailored to each disease, are required to measure the impact of HBA<sup>T87Q</sup> expression. “What we want to see in our drug products is that once we add our therapeutic HBA<sup>T87Q</sup>, we can restore the physiologic maturation of red blood cells <em>in vitro</em>.” In ?-thalassemia, HbA<sup>T87Q</sup> corrects the maturation arrest, while also correcting for sickle cell morphology in sickle cell disease.</p>   <p></p>   <p></p>   <p></p>   <h2 id="h-potency-assays-vector-copy-number-is-top"><strong>Potency Assays: Vector Copy Number is Top</strong></h2>   <p>Product potency is a key aspect of the overall process, as it provides a good indication as to whether the treatment is effective. Here, potency can be measured as a relative increase in the percent of mature erythroid cells or a relative decrease in the percent of sickled cells. Biavasco cautioned that it was not possible to show potency without accounting for the subject-specific background. “The absolute amount of <em>in vitro </em>mature erythroid cells or sickle cells deriving from the transduced cell is meaningless,” he said. “But as long as maturation percent increase or sickling percent decrease passes a specific threshold, the product is considered potent.”</p>   <p>Mechanism of action (MOA)-specific potency assays test for potential risks where a drug product contains LVV integrations that do not express the desired therapeutic protein or are are sequestered in a disproportionately small subset of cells. Testing for these risks necessarily increases the assay complexity, so there is a trade-off in information gained, time, and efficiency. “These assays can be measured in a semi-quantitative way,” said Biavasco. “But they come with a cost, and the cost is assay complexity.”</p>   <p>Part of the issue is the high impact of patient-to-patient variability, particularly with regard to the starting material. However, VCN is a valuable indicator to test for because it is simple, can be applied to many different diseases, and has a very quantifiable readout. “Cell editing measures are much stronger predictors of clinical efficacy compared to the MOA-specific readouts,” said Biavasco.</p>   <p></p>   <p></p>   <h2 id="h-future-indications-and-applications-for-potency-assays"><strong>Future Indications and Applications for Potency Assays</strong></h2>   <p>One of Biavasco's main conclusions from the presentation was that the VCN is a strong indicator of treatment efficacy to monitor for in potency assays. “Vector copy number and percent transduced cells nicely trend together,” he said, “and one can predict the other.” Drug products with VCNs above specification reliably achieve high and stable HBA<sup>T87Q</sup> expression. VCN is predictive of clinical efficacy, which Biavasco described as a “challenging accomplishment” for cell and gene therapy drug products.</p>   <blockquote class="wp-block-quote is-style-large"><p><strong><em>“Looking to the future, we would like gene therapy to be as accessible as possible."</em></strong></p></blockquote>   <p></p>   <p>“The VCN, and transduction measures in general, is our best predictor of clinical efficacy,” Biavasco said. Despite expressing the same therapeutic protein, ?-thalassemia and sickle cell disease require different MOA-specific potency assays. “In the end, the VCN correlates with more or less all the different potency assays,” added Biavasco. He rounded off by concluding that thoughtful reductions in testing complexity and cost can improve access to hematopoietic stem cell therapies for patients worldwide, while maintaining appropriate monitoring of drug products safety and quality. “Looking to the future, we would like gene therapy to be as accessible as possible to all patients in the world.”</p>   <p><br><a href="https://oxfordglobal.com/cell/" target="_blank" rel="noreferrer noopener"><em>Visit our Cell portal</em></a><em> to read more articles investigating the applications of stem cell therapies and potency assays. If you'd like to register your interest in our upcoming Cell UK: In-Person event, </em><a href="https://oxfordglobal.com/cell-series-uk/" target="_blank" rel="noreferrer noopener"><em>click here</em></a><em>.</em><br><br></p>  <div class="content-body-footer"> <div class="author-info text-no-gap"> <div class="author-about"> <h3> Speaker Biographies </h3> <p>Riccardo leads the hematopoietic stem cell (HSC) analytics group within Analytical Development at bluebird bio. He is responsible for development of drug product characterization assays, regulatory submission documents and interactions with regulatory agencies. Within HSC analytics, he compiles data generated by the group to advance product knowledge and foster comparability and correlative studies. The HSC analytics group supports clinical investigations and the execution of developed drug product characterization assays for Quality Control and Process Development.</p> </div> </div> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/The%20NIST%20Awards%20$1.5%20Million%20to%20Improve%20Standardisation%20in%20Regenerative%20Medicine.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine"> <h4> The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine </h4> <div class="abstract"> The National Institute of Standards and Technology (NIST) has given $1.5 million to two organisations to enhance regenerative medicine standards. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/kyoto-university-hospital-explores-the-potential-of-treating-type-1-diabetes-using-induced-pluripotent-stem-cells"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/Kyoto%20University%20Hospital%20Explores%20the%20Potential%20of%20Treating%20Type%201%20Diabetes%20Using%20Induced%20Pluripotent%20Stem%20Cells.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/kyoto-university-hospital-explores-the-potential-of-treating-type-1-diabetes-using-induced-pluripotent-stem-cells"> <h4> Kyoto University Hospital Explores the Potential of Treating Type 1 Diabetes Using Induced Pluripotent Stem Cells </h4> <div class="abstract"> Kyoto University Hospital aims to develop a treatment for severe Type 1 diabetes using induced pluripotent stem cells (iPSCs) reprogrammed to function as pancreatic islet cells. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/kyoto-university-hospital-explores-the-potential-of-treating-type-1-diabetes-using-induced-pluripotent-stem-cells" class="read-more-link">Read More</a> </div></a> </div> </div> </div> <div class="related-online-activities"> <h3 class="center">Related Online Activities</h3> Join the conversation with our upcoming Monthly Science Exchanges and Webinars: <div class="online-activity"> <div class="heading-smallcaps"> 01/11/24 </div> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing">Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</a> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/potency-assays-for-ceb2-thalassemia-and-sickle-cell-disease-gene-therapy-drug-products"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999271"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999271", "legacyPageId": "hubdb-177607186815-30817717-181072999271", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "68c364b2-86ae-4a9c-ab26-aff084b04da5", ticks: 1732669135591, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999271", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999271", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Potency Assays for Thalassemia and Sickle Cell Disease Gene Therapy Drug Products